secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2022-10-03T23:59:59+00:00
Accession:  0001193125-22-256110
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura reports Phase 2 interim data: 89% tumor control, significant growth rate reduction for choroidal melanoma
--------------------------------------------------------------------------------

- Interim Phase 2 data for belzupacap sarotalocan (AU-011) in early-stage choroidal melanoma show 88.9% (8/9) tumor control rate at therapeutic regimen.
- Statistically significant reduction in tumor growth rate of -0.296 mm/year (p=0.0007) vs. documented historical growth.
- Visual acuity preservation rate of 88.9% (8/9) in highest dose cohorts; most tumors were near fovea or optic disc.
- No dose-limiting toxicities or treatment-related serious adverse events reported; mild anterior inflammation in 20%.
- Data support planned pivotal program; company held virtual investor day on October 3, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312522256110/0001193125-22-256110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312522256110/d251752d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-256110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer